Bodyport

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Bodyport sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials 2 currently recruiting 1 completed upper quartile by trial count

Bodyport: 3 sponsored US clinical trials, 2 recruiting.

Bodyport sponsors 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. The most-studied condition in this pipeline is Peritoneal Dialysis (PD), with 1 trials.

Upper-quartile sponsor footprint

Bodyport sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

3 total, page 1 of 1

RECRUITING NA

Fluid Guided Heart Failure Treatment at the Cleveland Clinic

NCT07205120
RECRUITING

Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)

NCT07059962
COMPLETED

Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events

NCT04882449

Therapeutic Areas

Peritoneal Dialysis (PD) 1
End Stage Kidney Disease (ESRD) 1
Kidney Disease 1
Heart Failure 1

What is open in the Bodyport pipeline

2 recruiting of 3 indexed (67% open); 1 completed (33%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Peritoneal Dialysis (PD) (1 trial), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Bodyport: open-pipeline peers nationwide

Peers matched on 3 registered trials and 67% open enrollment, not the therapeutic-area sidebar.

Bodyport sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 234567 0%20%40%60%80% Total trials Recruiting share Bodyport10xBio22nd Century GroupAA SecordAAADRS Clinical Research CenterAbbisko Therapeutics CoABL BioAccelerated Cure Project for Multiple SclerosisAdvanced Reconstructive Surgery Alliance
Bodyport sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Bodyport sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 trials (± recruiting share)

Sponsors near 67% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Bodyport page

3 registered trials is a research-attention snapshot, not an endorsement of Bodyport or any single study.

  • 2 of Bodyport's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Peritoneal Dialysis (PD) is the condition Bodyport studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Peritoneal Dialysis (PD) trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Bodyport pipeline card: 3 registered trials from official public datasets.Report a data error.